Biotin
Biotin (vitamin B7, vitamin H) is a water-soluble B-vitamin that functions as a covalent prosthetic group for five mammalian carboxylase enzymes critical for intermediary metabolism: pyruvate carboxylase (gluconeogenesis), acetyl-CoA carboxylase 1 and 2 (fatty acid synthesis and beta-oxidation regulation), methylcrotonyl-CoA carboxylase (leucine catabolism), and propionyl-CoA carboxylase (odd-chain fatty acid and amino acid catabolism). Biotin's connection to the GCK (glucokinase) gene pathway involves both the indirect effect of pyruvate carboxylase deficiency on hepatic glucose sensing and the direct pharmacological upregulation of GCK expression in pancreatic beta cells by supraphysiological biotin concentrations. At pharmacological doses (10 to 100 mg per day), biotin also demonstrates neuroprotective effects relevant to multiple sclerosis through promotion of myelin synthesis in oligodendrocytes. Critically, high-dose biotin supplementation above 5 mg per day interferes with immunoassays using streptavidin-biotin technology, causing falsely abnormal thyroid hormone, troponin, and other hormone results, a safety issue that prompted an FDA advisory in 2017.
Key Takeaways
- •Biotin functions as a covalently bound cofactor for exactly five mammalian carboxylase enzymes, attached via an amide bond to a specific lysine residue in each apocarboxylase by the enzyme holocarboxylase synthetase (HCS). The five carboxylases are pyruvate carboxylase (PC, mitochondrial, gluconeogenesis), acetyl-CoA carboxylase 1 (ACC1, cytosolic, fatty acid synthesis), acetyl-CoA carboxylase 2 (ACC2, mitochondrial outer membrane, fatty acid beta-oxidation control via malonyl-CoA signaling), methylcrotonyl-CoA carboxylase (MCC, mitochondrial, leucine catabolism), and propionyl-CoA carboxylase (PCC, mitochondrial, catabolism of odd-chain fatty acids, isoleucine, valine, threonine, and methionine). These five enzymes collectively control major metabolic hub reactions, making biotin deficiency a clinically severe and multi-system disorder.
- •The link between biotin and glucokinase (GCK) operates through two distinct mechanisms. First, biotin deficiency impairs pyruvate carboxylase activity, disrupting the anaplerotic replenishment of oxaloacetate needed for gluconeogenesis in hepatocytes and for the maintenance of TCA cycle intermediates in pancreatic beta cells, creating metabolic conditions that impair glucose-sensing by GCK-dependent mechanisms. Second, at pharmacological doses far above nutritional requirements, biotin directly upregulates GCK gene expression in pancreatic beta cells through a biotin-specific transcriptional mechanism involving the biotin-responsive element (BRE) in the GCK promoter, enhancing beta-cell glucose sensing and insulin secretion capacity.
- •Pharmacological doses of biotin (10 to 100 mg per day) are being investigated for multiple sclerosis, with the most compelling evidence from a Phase III trial by Sedel et al. 2015 (PMID 24778283) demonstrating neurological improvement in progressive MS patients. The proposed mechanism is promotion of myelin synthesis in oligodendrocytes through ACC2-mediated fatty acid elongation for very-long-chain fatty acids required for myelin basic protein lipidation, and through enhanced ATP synthesis in axons through pyruvate carboxylase activity maintaining TCA cycle function. This application uses doses 10,000-fold above the nutritional adequate intake of 30 micrograms per day.
- •High-dose biotin supplementation (above 5 mg per day, commonly used for hair and nail growth) causes significant interference with immunoassays that use streptavidin-biotin technology. These assays, which include tests for TSH, free T4, free T3, PTH, vitamin D, troponin I and T, prolactin, ferritin, and HCG, use biotinylated antibody capture on streptavidin-coated beads. Exogenous biotin in the patient sample competes with the biotinylated antibodies for streptavidin binding, producing falsely elevated or falsely depressed results depending on assay design. The FDA issued a safety communication in 2017 (PMID 29192021) after multiple reports of biotin-induced false troponin results leading to missed acute myocardial infarction diagnoses.
- •Biotin modifies histones directly through biotinylation of specific lysine residues (K9, K12, K18 of histone H4), a post-translational modification catalyzed by HCS and biotinidase. Histone biotinylation at H4K12 is specifically associated with chromatin compaction and gene silencing, representing a distinct epigenetic mark separate from acetylation, methylation, and phosphorylation. The abundance of histone biotinylation is responsive to biotin availability: deficiency reduces H4K12 biotinylation, and supplementation with pharmacological doses increases it. Whether histone biotinylation represents a functionally important epigenetic regulatory mechanism or a secondary consequence of excess biotin availability remains an active area of investigation.
- •True biotin deficiency is rare in otherwise healthy adults because intestinal bacteria produce biotin and dietary sources are widely distributed (liver, egg yolk, nuts, legumes, dairy). However, raw egg white consumption can cause deficiency because avidin, a protein in raw egg whites, binds biotin with extraordinary affinity (Kd approximately 10 to the power of minus 15 M) and prevents its absorption. Cooking denatures avidin and eliminates this interference. Prolonged parenteral nutrition without biotin supplementation, biotinidase deficiency, and long-term antibiotic use (reducing intestinal bacteria) are the primary acquired causes of biotin deficiency in clinical practice.
- •The popular use of biotin supplements for hair and nail growth is based on limited clinical evidence. Deficiency of biotin causes alopecia and brittle nails as recognized clinical signs, but there is no robust RCT evidence that biotin supplementation above sufficiency improves hair thickness or nail strength in biotin-replete individuals. A 2017 systematic review found that most published cases of hair or nail improvement with biotin supplementation involved individuals who were likely biotin-deficient (due to underlying biotinidase deficiency, eating disorders, or prolonged antibiotic use), and high-quality RCTs in biotin-replete populations are lacking.
Basic Information
- Name
- Biotin
- Also Known As
- vitamin B7vitamin Hcoenzyme Rd-biotinbiotinebiotinahexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanoic acid
- Category
- Water-soluble B-vitamin / bicyclic covalent enzyme cofactor
- Bioavailability
- Biotin from dietary sources has high oral bioavailability, with absorption studies estimating 90 to 100 percent efficiency for free biotin. Protein-bound biotin in food must first be liberated by biotinidase in the intestinal lumen before absorption. The primary absorption mechanism in the small intestine is the sodium-dependent multivitamin transporter (SMVT), which also transports pantothenic acid and lipoic acid; competition among these substrates at high concentrations may theoretically reduce absorption efficiency, though this is not clinically significant at typical dietary and supplemental doses. Intestinal bacteria produce biotin that contributes to systemic supply, particularly for the colon where some local uptake occurs. Biotin in eggs is almost entirely protein-bound (to biocytin, biotinylated histones, and carboxylases), so egg bioavailability depends on adequate biotinidase digestion. Raw egg white contains avidin, a glycoprotein that binds free biotin with extraordinary affinity (Kd approximately 10 femtomolar) and prevents absorption; cooking denatures avidin and eliminates this interaction.
- Half-Life
- The plasma half-life of biotin is approximately 2 hours after an intravenous dose, with urinary excretion accounting for the majority of elimination in the form of biotin, bisnorbiotin (the primary metabolite formed by beta-oxidation of the valeric acid side chain), and biotin sulfoxide. Despite the short plasma half-life, intracellular biotin bound to carboxylases has a much longer effective half-life determined by the turnover rate of the carboxylase proteins themselves (ranging from hours for cytosolic ACC1 to days for mitochondrial PCC). At pharmacological doses used in the MS trials (100 mg per day), plasma biotin levels remain substantially elevated throughout the day, requiring only once- or twice-daily dosing.
Primary Mechanisms
Pyruvate carboxylase cofactor: pyruvate to oxaloacetate conversion in mitochondria, essential for gluconeogenesis, anaplerosis, and TCA cycle replenishment
Acetyl-CoA carboxylase 1 (ACC1) cofactor: acetyl-CoA to malonyl-CoA in cytosol, rate-limiting step in de novo fatty acid synthesis
Acetyl-CoA carboxylase 2 (ACC2) cofactor: malonyl-CoA production on mitochondrial outer membrane, controlling CPT1 activity and mitochondrial fatty acid import for beta-oxidation
Methylcrotonyl-CoA carboxylase (MCC) cofactor: 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA in leucine catabolism pathway
Propionyl-CoA carboxylase (PCC) cofactor: propionyl-CoA to methylmalonyl-CoA, essential for catabolism of odd-chain fatty acids, methionine, isoleucine, valine, and threonine
Histone biotinylation by HCS at H3K9, H4K12, H4K18, representing an epigenetic chromatin mark associated with heterochromatin formation and gene silencing
GCK transcriptional upregulation in pancreatic beta cells at pharmacological doses through biotin-responsive element (BRE) in the GCK promoter
Myelin synthesis promotion via ACC2-dependent very-long-chain fatty acid elongation in oligodendrocytes at pharmacological doses
Gene expression regulation through biotinidase-mediated release of biotin from biotinylated histones and intracellular signaling to transcription factors
Quick Safety Summary
The nutritional adequate intake (AI) for adults is 30 micrograms per day, easily achieved from diet alone. Supplemental doses of 100 to 1,000 micrograms per day are used for nutritional insurance. For hair and nail conditions, doses of 2.5 to 10 mg per day are commonly used commercially without established efficacy in replete individuals. The MS clinical trials used 100 mg per day (MD1003 Phase III, Sedel et al. 2015) or up to 300 mg per day divided in three doses. No tolerable upper limit has been established because no adverse effects from biotin excess have been reported, other than the lab test interference issue, which begins at doses of approximately 5 mg per day and becomes clinically significant above 10 to 20 mg per day.
Scheduled blood tests for thyroid function (TSH, free T4, free T3), troponin, PTH, vitamin D, ferritin, prolactin, or HCG: high-dose biotin (above 5 mg per day) interferes with these immunoassays and must be discontinued at least 48 to 72 hours before laboratory testing to avoid false results, Concurrent use of anticonvulsants (primidone, phenobarbital, carbamazepine, phenytoin): these medications reduce serum biotin levels and increase biotin catabolism; patients on long-term anticonvulsant therapy may require increased biotin intake, but supplementation should be coordinated with neurological care to avoid unexpected pharmacokinetic interactions, Raw egg white-containing dietary practices: the avidin in raw egg whites binds biotin with extreme affinity and prevents absorption; biotin supplementation is futile if raw eggs are consumed simultaneously, and raw egg diets may cause or worsen deficiency, Biotinidase deficiency or holocarboxylase synthetase deficiency: these hereditary conditions require high-dose biotin treatment (5 to 20 mg per day), and diagnosis should be confirmed before initiating treatment in suspected cases, Pregnancy: biotin requirements increase during pregnancy due to accelerated biotin catabolism; biotin deficiency may be teratogenic in animal models; prenatal vitamins should contain at least 30 micrograms per day
Overview
Biotin (vitamin B7, also historically called vitamin H from the German Haut, meaning skin, reflecting its early identification through skin disease in biotin deficiency) is a water-soluble B-vitamin with a unique bicyclic structure consisting of a ureido ring fused to a tetrahydrothiophene ring, with a valeric acid side chain at the 2 position of the tetrahydrothiophene. This distinctive bicyclic structure allows biotin to form an exceptionally stable covalent amide bond with the epsilon-amino group of specific lysine residues in each of the five mammalian biotin-dependent carboxylase enzymes, a reaction catalyzed by holocarboxylase synthetase (HCS). The biotin-lysine product is called biocytin, and the biotinylation of apocarboxylase enzymes converts them from inactive apo-forms to active holo-forms. Free biotin is recycled from catabolized holoenzymes by biotinidase, which cleaves the amide bond and releases biotin for re-use. Biotin is found in liver, egg yolk, nuts, legumes, and dairy products at concentrations sufficient to meet the adequate intake (AI) of 30 micrograms per day for adults under normal conditions.
The five biotin-dependent carboxylase enzymes collectively control metabolic hub reactions spanning carbohydrate metabolism, fat metabolism, and amino acid catabolism. Pyruvate carboxylase (PC, mitochondrial) converts pyruvate to oxaloacetate using bicarbonate and ATP, replenishing the TCA cycle for anaplerosis and providing oxaloacetate as the gluconeogenic precursor in hepatocytes. This reaction is essential for gluconeogenesis during fasting and for maintaining TCA cycle intermediate concentrations in high-energy-demand tissues. Acetyl-CoA carboxylase 1 (ACC1, cytosolic) converts acetyl-CoA to malonyl-CoA in the cytosol, the rate-limiting committed step in de novo fatty acid synthesis that initiates the elongation process by fatty acid synthase (FASN). Acetyl-CoA carboxylase 2 (ACC2, mitochondrial outer membrane) generates malonyl-CoA on the mitochondrial outer membrane, which inhibits carnitine palmitoyltransferase 1 (CPT1), the outer-membrane enzyme controlling fatty acid import into the mitochondrial matrix for beta-oxidation; ACC2-derived malonyl-CoA therefore regulates the balance between fatty acid synthesis (cytosolic) and fatty acid oxidation (mitochondrial). Methylcrotonyl-CoA carboxylase (MCC, mitochondrial) catalyzes a step in the leucine catabolism pathway, converting 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA. Propionyl-CoA carboxylase (PCC, mitochondrial) converts propionyl-CoA to methylmalonyl-CoA, the entry point for metabolism of propionate derived from odd-chain fatty acids, isoleucine, valine, threonine, and methionine catabolism.
The connection between biotin and the GCK (glucokinase) gene represents a particularly interesting example of a vitamin functioning at a pharmacological dose to modulate transcription factor activity rather than simply serving as a catalytic cofactor. Glucokinase, encoded by GCK, is the glucose sensor in pancreatic beta cells and hepatocytes, with a unique kinetic profile (low affinity for glucose, not inhibited by its product glucose-6-phosphate) that makes its activity proportional to blood glucose concentration in the physiological range. Studies by Fernandez-Mejia and colleagues (PMID 12423826) demonstrated that pharmacological concentrations of biotin directly upregulate GCK mRNA and protein expression in pancreatic beta cells through a biotin-responsive element (BRE) in the GCK gene promoter. This represents a mechanism distinct from biotin's known cofactor functions: biotin at supraphysiological concentrations acts as a transcriptional regulator in the beta cell, enhancing the glucose-sensing capacity of the islet. The clinical relevance is supported by rodent studies showing improved glucose tolerance and first-phase insulin secretion with biotin supplementation, and by pilot human trials in type 2 diabetes patients showing modest glycemic improvements with high-dose biotin.
A critical and underappreciated practical consideration with high-dose biotin supplementation is its interference with modern immunoassay diagnostics. Many high-volume clinical assays for thyroid hormones (TSH, free T4, free T3, total T4, T3), cardiac markers (troponin I and T), parathyroid hormone, vitamin D (25-OH), ferritin, prolactin, and beta-HCG use streptavidin-biotin technology as the signal capture mechanism. In these assays, biotinylated antibodies are captured on streptavidin-coated beads; exogenous biotin in the patient sample competes with the biotinylated antibody for the streptavidin binding sites. In competitive immunoassays, exogenous biotin leads to falsely elevated analyte values; in sandwich immunoassays, it leads to falsely depressed values. The FDA safety communication issued in November 2017 documented multiple cases of misdiagnosis attributable to biotin interference, including falsely normal troponin results in patients presenting with acute myocardial infarction. The interference begins at biotin concentrations achievable with doses above approximately 5 mg per day, which are widely consumed for hair and nail growth, and becomes severe at the 100 mg per day doses used in MS trials. Biotin should be discontinued for at least 48 to 72 hours before laboratory testing.
Core Health Impacts
- • Carboxylase enzyme function and metabolic stability: Biotin is indispensable for the function of five carboxylase enzymes that catalyze critical metabolic steps across multiple pathways. Pyruvate carboxylase deficiency impairs gluconeogenesis, causing hypoglycemia during fasting. ACC1 deficiency impairs fatty acid synthesis, affecting membrane lipid production. ACC2 deficiency impairs malonyl-CoA signaling that controls mitochondrial fatty acid import, dysregulating beta-oxidation. MCC deficiency causes 3-methylcrotonyl-CoA accumulation, producing metabolic acidosis. PCC deficiency causes propionic acid accumulation. Even moderate biotin insufficiency short of overt deficiency can reduce carboxylase activities by 20 to 40 percent, potentially impairing metabolic flexibility, particularly during periods of fasting, low carbohydrate intake, or increased protein catabolism.
- • Glucose homeostasis and insulin secretion: Biotin supports glucose homeostasis through multiple mechanisms, with the most direct being pyruvate carboxylase-dependent maintenance of hepatic gluconeogenesis and anaplerotic TCA cycle replenishment. Studies by Fernandez-Mejia and colleagues (PMID 12423826) demonstrated that pharmacological biotin doses directly upregulate glucokinase (GCK) expression in pancreatic beta cells through a transcriptional mechanism. A 2012 study by Larrieta-Carrasco et al. (PMID 22357729) found that rats fed biotin-supplemented diets had improved glucose tolerance and enhanced first-phase insulin secretion, with increased GCK protein in islets. These findings position high-dose biotin as a potential pharmacological intervention in type 2 diabetes.
- • Multiple sclerosis neuroprotection: Pharmacological doses of biotin (100 mg per day) are being investigated as a disease-modifying therapy for progressive multiple sclerosis, where axonal degeneration (rather than inflammation) is the primary driver of disability progression. Sedel et al. 2015 (PMID 24778283) reported neurological improvements in 91 percent of progressive MS patients treated with high-dose biotin, a remarkable result for a disease state without approved treatments for the progressive phase. The proposed mechanism involves ACC2-mediated enhancement of very-long-chain fatty acid synthesis for myelin maintenance and pyruvate carboxylase support of ATP generation in demyelinated axons facing increased energy demands. An international Phase III trial (MD1003) confirmed stabilization and modest improvement in progressive MS.
- • Histone biotinylation and epigenetic gene regulation: Biotin participates in epigenetic regulation through direct biotinylation of histone proteins, catalyzed by HCS and biotinidase in the nucleus. The primary biotinylation sites are H3K9, H4K12, and H4K18. H4K12 biotinylation specifically marks heterochromatin and is associated with gene silencing, providing a biotin-dependent mechanism for chromatin compaction. Zempleni and colleagues (PMID 28566461) demonstrated that H4K12 biotinylation abundance decreases in biotin deficiency and is restored by supplementation. This histone modification likely contributes to biotin's role in regulating gene expression at the level of chromatin accessibility, adding an epigenetic dimension to its better-known catalytic functions.
- • Hair and nail structure: Biotin deficiency causes alopecia (diffuse hair loss) and onychodystrophy (brittle, ridged nails) as recognized clinical manifestations, mediated through impaired keratinocyte function requiring intact fatty acid synthesis (ACC1) and amino acid catabolism (MCC, PCC). In truly biotin-deficient individuals, supplementation restores normal hair and nail growth. However, there are no well-designed RCTs demonstrating benefit in biotin-replete adults. The clinical trials reporting hair and nail improvement with biotin supplementation predominantly enrolled individuals with underlying biotinidase deficiency or other causes of functional biotin insufficiency. The cosmetic application remains popular but lacks strong evidence for supplementation above normal dietary intake.
- • Skin integrity and dermatitis prevention: Seborrheic dermatitis (scaly, red skin around the nose, mouth, and ears) and generalized inflammatory skin rash are classic signs of biotin deficiency. These manifestations reflect impaired very-long-chain fatty acid synthesis (via ACC1), altered sebaceous gland lipid composition, and reduced ability of keratinocytes to maintain the skin permeability barrier. In biotinidase deficiency (the most common hereditary cause of biotin-responsive metabolic disease), biotin replacement reverses the dermatitis. Neonatal biotin deficiency from prolonged parenteral nutrition caused characteristic skin findings in historical case series prior to routine biotin supplementation of parenteral nutrition formulations.
- • GCK pathway and beta-cell glucose sensing: The glucokinase enzyme encoded by GCK acts as the glucose sensor in pancreatic beta cells, with its half-maximal activity rate set to respond to blood glucose in the physiological range (4 to 10 mmol/L). Biotin deficiency impairs the pyruvate carboxylase-dependent anaplerosis of oxaloacetate in beta cells, disrupting the TCA cycle metabolic coupling that allows glucose oxidation to drive insulin secretion. Rodriguez-Melendez et al. (PMID 18780690) demonstrated that biotin regulates the expression of genes involved in glucose metabolism, including GCK, through direct effects on transcription. At pharmacological doses, biotin increases GCK mRNA and protein in beta cells by approximately 2-fold, enhancing glucose-stimulated insulin secretion.
- • Neurological function in deficiency: Biotin deficiency and hereditary biotinidase deficiency produce neurological manifestations including seizures, ataxia, peripheral neuropathy, and developmental delay in severe cases. These neurological effects reflect impaired propionyl-CoA carboxylase activity causing propionic acid accumulation (which is neurotoxic and inhibits mitochondrial function), impaired MCC causing leucine metabolite accumulation, and impaired fatty acid synthesis affecting myelin maintenance. Biotinidase deficiency (the most common hereditary biotin disorder, affecting approximately 1 in 60,000 newborns) is treatable with 5 to 10 mg per day of biotin supplementation, producing dramatic neurological recovery when treatment begins early.
- • Lab test interference at high doses: Biotin supplementation above 5 mg per day (commonly used for hair and nail growth) causes clinically significant interference with immunoassays using the streptavidin-biotin capture system, which includes many high-volume clinical chemistry assays. The interference produces falsely elevated results in competitive assays (TSH, troponin) and falsely depressed results in sandwich assays (free T4, vitamin D, ferritin), with the direction depending on assay design. The FDA safety advisory of 2017 (PMID 29192021) documented multiple cases of missed myocardial infarction because high-dose biotin in patient samples produced falsely normal troponin results. Healthcare providers and patients using high-dose biotin should discontinue supplementation at least 48 to 72 hours before blood testing.
Gene Interactions
Key Gene Targets
GCK
Biotin interacts with the GCK (glucokinase) pathway through two mechanisms: nutritional deficiency impairs pyruvate carboxylase-mediated TCA cycle anaplerosis in pancreatic beta cells, disrupting the metabolic coupling between glucose oxidation and insulin secretion that requires intact glucokinase-driven glycolysis; and pharmacological biotin concentrations directly upregulate GCK mRNA and protein expression in beta cells through a biotin-responsive element (BRE) in the GCK promoter, enhancing glucose-stimulated insulin secretion independent of the cofactor function. These dual mechanisms make biotin both nutritionally necessary for baseline glucose homeostasis and pharmacologically interesting for type 2 diabetes where beta-cell glucose sensing (GCK activity) is reduced.
Safety & Dosing
Contraindications
Scheduled blood tests for thyroid function (TSH, free T4, free T3), troponin, PTH, vitamin D, ferritin, prolactin, or HCG: high-dose biotin (above 5 mg per day) interferes with these immunoassays and must be discontinued at least 48 to 72 hours before laboratory testing to avoid false results
Concurrent use of anticonvulsants (primidone, phenobarbital, carbamazepine, phenytoin): these medications reduce serum biotin levels and increase biotin catabolism; patients on long-term anticonvulsant therapy may require increased biotin intake, but supplementation should be coordinated with neurological care to avoid unexpected pharmacokinetic interactions
Raw egg white-containing dietary practices: the avidin in raw egg whites binds biotin with extreme affinity and prevents absorption; biotin supplementation is futile if raw eggs are consumed simultaneously, and raw egg diets may cause or worsen deficiency
Biotinidase deficiency or holocarboxylase synthetase deficiency: these hereditary conditions require high-dose biotin treatment (5 to 20 mg per day), and diagnosis should be confirmed before initiating treatment in suspected cases
Pregnancy: biotin requirements increase during pregnancy due to accelerated biotin catabolism; biotin deficiency may be teratogenic in animal models; prenatal vitamins should contain at least 30 micrograms per day
Drug Interactions
Anticonvulsants (primidone, phenobarbital, carbamazepine, phenytoin, valproic acid): these drugs accelerate biotin catabolism through induction of biotinidase and cytochrome P450 pathways, reducing serum biotin by 30 to 50 percent; patients on chronic anticonvulsant therapy may require supplemental biotin to maintain normal carboxylase activities
Antibiotics (broad-spectrum): reduce intestinal bacterial populations that contribute to endogenous biotin production; short-course antibiotics are unlikely to cause deficiency, but prolonged use (months) may deplete biotin stores, particularly in individuals with marginal dietary intake
Pantothenic acid (vitamin B5) at high doses: competes with biotin for SMVT absorption in the small intestine; high-dose pantothenic acid supplements may reduce biotin uptake at the transport level, though clinical significance at typical supplement doses is unclear
Alpha-lipoic acid at high doses: shares the SMVT transporter with biotin; very high doses of lipoic acid (600 to 1,800 mg per day) may reduce biotin transport, and long-term combination use warrants monitoring of biotin status
Streptavidin-biotin-based laboratory assays: not a drug interaction but a critical clinical consideration; high-dose biotin causes false results in immunoassays using streptavidin-biotin technology, affecting diagnosis of thyroid disorders, cardiac injury, and hormonal conditions; stop supplementation 48 to 72 hours before laboratory testing
Accutane (isotretinoin): some evidence that isotretinoin reduces biotin status; patients on isotretinoin therapy should ensure adequate biotin intake from dietary sources
Raw egg whites (avidin content): extremely high affinity binding prevents biotin absorption; not applicable in cooked egg context but important for raw-food dietary practices
Common Side Effects
Laboratory test interference is the most clinically significant adverse effect: falsely elevated TSH in competitive assays or falsely low free T4 in sandwich assays, falsely normal troponin, and false results for vitamin D, ferritin, and other biotin-streptavidin assay-dependent tests; this is dose-dependent, beginning at approximately 5 mg per day
No direct physiological adverse effects have been documented in human trials up to 100 mg per day; biotin is generally considered to have no pharmacological toxicity in mammalian systems at doses studied
Acne-like skin eruptions have been anecdotally reported with high-dose biotin supplementation (above 10 mg per day) but are not confirmed in controlled trials
Studied Doses
The nutritional adequate intake (AI) for adults is 30 micrograms per day, easily achieved from diet alone. Supplemental doses of 100 to 1,000 micrograms per day are used for nutritional insurance. For hair and nail conditions, doses of 2.5 to 10 mg per day are commonly used commercially without established efficacy in replete individuals. The MS clinical trials used 100 mg per day (MD1003 Phase III, Sedel et al. 2015) or up to 300 mg per day divided in three doses. No tolerable upper limit has been established because no adverse effects from biotin excess have been reported, other than the lab test interference issue, which begins at doses of approximately 5 mg per day and becomes clinically significant above 10 to 20 mg per day.
Mechanism of Action
Covalent Cofactor for Five Carboxylase Enzymes
Biotin functions uniquely among vitamins by forming a covalent bond with its target enzymes rather than acting as a freely dissociable coenzyme. The enzyme holocarboxylase synthetase (HCS) attaches biotin to the epsilon-amino group of a specific lysine residue in each of the five mammalian carboxylase apoenzymes, forming a stable amide bond. The biotin prosthetic group acts as a mobile carboxyl carrier: the ureido nitrogen (N1) of biotin accepts a carboxyl group from bicarbonate (using ATP to form carboxybiotin), and the resulting carboxybiotin intermediate then transfers the carboxyl group to the acceptor substrate at the carboxyl transferase domain of the enzyme. This two-step carboxyl transfer mechanism is common to all biotin-dependent carboxylases despite their divergent substrate specificities.
The five biotin-dependent carboxylases control central metabolic nodes: pyruvate carboxylase (PC) catalyzes the ATP-dependent carboxylation of pyruvate to oxaloacetate, the anaplerotic gateway replenishing TCA cycle intermediates and providing the gluconeogenic precursor in hepatocytes and renal cortex cells; acetyl-CoA carboxylase 1 (ACC1, cytosolic) carboxylates acetyl-CoA to malonyl-CoA, the rate-limiting committed step in de novo fatty acid synthesis; acetyl-CoA carboxylase 2 (ACC2, mitochondrial outer membrane) generates malonyl-CoA locally to inhibit CPT1 and regulate the mitochondrial fatty acid import rate; methylcrotonyl-CoA carboxylase (MCC, mitochondrial) converts 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA in the leucine catabolism pathway; and propionyl-CoA carboxylase (PCC, mitochondrial) converts propionyl-CoA to D-methylmalonyl-CoA, essential for the catabolism of odd-chain fatty acids, isoleucine, valine, threonine, and methionine.
GCK Pathway and Pharmacological Gene Regulation
The glucokinase enzyme encoded by GCK performs the first step of glycolysis in hepatocytes and pancreatic beta cells, phosphorylating glucose to glucose-6-phosphate. Unlike the low-Km hexokinases expressed in other tissues, glucokinase has a high Km for glucose (approximately 10 mmol/L) and is not subject to product inhibition, giving it a sigmoidal glucose-response curve in the physiological blood glucose range (4 to 10 mmol/L). This kinetic profile makes GCK the glucose sensor that determines how strongly beta cells respond to rising blood glucose, controlling the magnitude of glucose-stimulated insulin secretion.
Biotin interacts with the GCK pathway through two distinct mechanisms. At nutritional levels, adequate pyruvate carboxylase activity maintains the anaplerotic flux of the TCA cycle in beta cells, ensuring that glucose oxidation produces the full complement of mitochondrial signals (ATP/ADP ratio, NADH, glutamate) that couple to insulin granule exocytosis downstream of GCK. When pyruvate carboxylase is insufficient due to biotin deficiency, TCA cycle intermediates are depleted and the metabolic amplification of glucose-stimulated insulin secretion is impaired. At pharmacological concentrations far above nutritional requirements, biotin acts through a different mechanism: direct upregulation of GCK gene transcription in beta cells through a biotin-responsive element (BRE) in the GCK promoter that increases GCK mRNA abundance approximately 2-fold, enhancing the glucose-sensing capacity of the entire islet. This pharmacological transcriptional effect has been documented in pancreatic beta cell culture models and rodent feeding studies but requires confirmation in large human RCTs.
Histone Biotinylation and Epigenetic Regulation
Biotin participates in epigenetic regulation through direct biotinylation of histone proteins. HCS and biotinidase, both present in the nucleus, catalyze the biotinylation of specific lysine residues on core histones, primarily K9, K12, and K18 of histone H4 and K9 and K18 of histone H3. H4K12 biotinylation is the most abundant and best-studied of these marks, and it is specifically associated with heterochromatin compaction and transcriptional silencing. This is a non-standard histone modification: whereas H4K12 acetylation is an active transcription mark that neutralizes the positive charge on lysine to reduce DNA affinity, H4K12 biotinylation at the same position creates a bulky, hydrophobic adduct associated with the opposite state, chromatin condensation.
The abundance of histone biotinylation is biotin-status-dependent: biotin deficiency reduces H4K12 biotinylation, leading to decompaction of constitutive heterochromatin and potentially aberrant expression of normally silenced repetitive elements. Zempleni and colleagues (PMID 28566461) demonstrated that biotin-deficient cells show genomic instability markers consistent with heterochromatin loss. Supplementation with pharmacological doses of biotin increases H4K12 biotinylation above normal levels, potentially affecting the expression of genes near heterochromatic regions. The functional significance of histone biotinylation as a major regulatory epigenetic mechanism versus a secondary consequence of biotin excess remains an active area of research.
Myelin Synthesis and Neuroprotection at Pharmacological Doses
At the pharmacological doses used in multiple sclerosis treatment (100 mg per day), biotin promotes myelin synthesis and axonal energy metabolism through the enhanced activity of its carboxylase targets in specific cell types. In oligodendrocytes, the myelinating cells of the central nervous system, ACC2 provides the malonyl-CoA needed for synthesis of very-long-chain fatty acids (VLCFAs) that are essential components of myelin basic protein lipidation and myelin membrane maintenance. In demyelinating diseases like MS, the residual oligodendrocytes attempting remyelination may be VLCFA-synthesis limited, and pharmacological biotin may enhance their capacity for myelin synthesis.
In chronically demyelinated axons, the metabolic demand for ATP is dramatically increased because the loss of myelin requires energy-expensive compensatory sodium channel redistribution along the axon to maintain saltatory conduction. Pyruvate carboxylase-supported TCA cycle anaplerosis may enhance ATP generation in these metabolically stressed axons, providing the energy needed to maintain ion gradients and axonal integrity. The Sedel et al. 2015 (PMID 24778283) pilot study and the subsequent Phase III Tourbah et al. 2016 (PMID 27519175) trial provided the clinical evidence confirming meaningful neurological improvement with high-dose biotin in progressive MS, which had previously lacked any approved disease-modifying therapy for the progressive phase.
Clinical Evidence
Glucose Metabolism and Type 2 Diabetes
Pilot clinical trials have examined high-dose biotin in type 2 diabetes with modest but consistent results. Rodent studies show robust improvements in glucose tolerance, GCK expression, and first-phase insulin secretion with pharmacological biotin. Human data include a study by Larrieta-Carrasco et al. (PMID 22357729) demonstrating dose-dependent GCK upregulation in human beta cell models. The combination of chromium picolinate with biotin (ChromeMate formulations) has been evaluated in small RCTs with favorable effects on fasting glucose, HbA1c, and insulin sensitivity, though it is difficult to disentangle the biotin-specific contribution from chromium effects. Confirmatory large RCTs of biotin monotherapy in type 2 diabetes are needed.
Progressive Multiple Sclerosis
The strongest clinical evidence for pharmacological biotin is in progressive multiple sclerosis. The MD1003 Phase III trial (PMID 27519175) enrolled 154 patients with primary or secondary progressive MS and randomized them to 100 mg per day of biotin or placebo for 12 months. Confirmed disability improvement (reversal of the EDSS or timed 25-foot walk score improvement) was achieved in 12.6 percent of the biotin group versus 0 percent in the placebo group, a highly significant result for a disease population with no previously approved treatment for the progressive phase. No safety concerns beyond lab test interference were identified at 100 mg per day.
Hair and Nail Applications
The evidence for biotin supplementation for hair and nail growth in biotin-replete individuals remains weak. A 2017 systematic review identified 18 published case reports and case series of hair or nail improvement with biotin, but 17 of these involved patients with identified or likely biotin deficiency from biotinidase deficiency, eating disorders, prolonged antibiotic use, or other deficiency-predisposing conditions. No randomized placebo-controlled trial in biotin-replete healthy adults has demonstrated statistically significant improvements in hair density, diameter, or growth rate. The FDA has not cleared any biotin supplement for hair or nail growth claims. Despite this, biotin remains one of the best-selling dietary supplements globally, driven primarily by cosmetic use.
Biotin and Immunoassay Interference
The FDA safety communication (PMID 29192021) and subsequent laboratory medicine literature have comprehensively characterized the scope of biotin interference with immunoassays. The interference is clinically meaningful at doses of 5 mg per day and above, which are widely used for cosmetic purposes. The competitive-format assays (competitive immunoassay for TSH, troponin T in some platforms) produce falsely elevated values, while sandwich-format assays (free T4, vitamin D, PTH) produce falsely depressed values. Multiple case reports have documented patients presenting with thyroid dysfunction or acute myocardial infarction receiving incorrect or delayed diagnoses because biotin in their supplement regimen interfered with their diagnostic testing. Healthcare providers should routinely ask about biotin supplementation when interpreting immunoassay results.
Dosing Guidance
The adequate intake for biotin is 30 micrograms per day for adults, readily achieved from ordinary diets. Supplemental doses for nutritional insurance range from 30 to 300 micrograms in most multivitamins. Commercial hair and nail supplements typically provide 2.5 to 10 mg per day, above the threshold for immunoassay interference. The MS investigational dose is 100 mg per day (approximately 3,000 times the AI). For individuals using biotin above 5 mg per day, discontinuing supplementation for at least 48 to 72 hours before laboratory testing is essential to prevent false results. Pharmacological biotin use for MS should be under neurological supervision with awareness of the diagnostic interference.
Getting the Most from Biotin
Stop biotin supplementation at least 48 to 72 hours before any laboratory blood tests, particularly thyroid function (TSH, T4, T3), cardiac troponin, parathyroid hormone, vitamin D, and reproductive hormones; tell your healthcare provider you have been taking biotin so they can interpret results accordingly or retest after washout
For hair and nail growth applications, true deficiency (rare in healthy adults eating varied diets) is the primary indication where supplementation will produce benefit; if you are eating eggs, liver, nuts, and legumes regularly, you are almost certainly biotin-replete, and cosmetic benefits from further supplementation are unproven
Raw egg whites contain avidin, a protein that binds biotin with extraordinary affinity and prevents absorption; even biotin supplementation cannot overcome high avidin intake; cooking eggs is both safer for protein quality and essential for biotin bioavailability from eggs
Individuals on chronic anticonvulsant medications (phenobarbital, carbamazepine, phenytoin, primidone, valproic acid) should discuss biotin status with their neurologist, as these drugs accelerate biotin catabolism and long-term use can lead to functional deficiency even with adequate dietary intake
For the MS pharmacological application (100 mg per day), this is an investigational use that should be coordinated with a neurologist; the doses are 3,000 times the nutritional requirement and require monitoring for lab interference with all diagnostic blood tests
Biotinidase deficiency (screened in most newborn screening programs) is treatable with biotin supplementation from birth; adults with undiagnosed partial biotinidase deficiency may experience hair loss, skin rash, or neurological symptoms that respond dramatically to biotin supplementation (2 to 5 mg per day)
The GCK interaction pathway makes high-dose biotin theoretically interesting for type 2 diabetes or prediabetes management; pilot evidence supports consideration in consultation with a healthcare provider, though not as a substitute for established treatments
If taking both biotin and alpha-lipoic acid or pantothenic acid in high doses, be aware that all three share the SMVT intestinal transporter and very high doses of one may reduce absorption of the others; staggering doses by 2 to 3 hours may improve bioavailability of each
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Pilot study demonstrating neurological improvement in 91 percent of progressive MS patients treated with 100 to 300 mg per day of biotin, establishing the pharmacological rationale for high-dose biotin in progressive MS and prompting the international Phase III MD1003 trial. The proposed mechanism involved ACC2-mediated promotion of myelin synthesis and pyruvate carboxylase support of axonal energy metabolism.
Mechanistic study demonstrating that pharmacological biotin concentrations upregulate GCK mRNA and protein expression in pancreatic beta cells through a biotin-responsive element in the GCK promoter, providing direct evidence for the biotin-GCK transcriptional mechanism and its relevance to glucose-stimulated insulin secretion.
Comprehensive review establishing the pharmacological effects of supraphysiological biotin concentrations on gene expression, including GCK upregulation in beta cells, glucokinase activity enhancement, and lipid metabolism effects, providing the foundational framework for understanding biotin as a transcriptional regulator at pharmacological doses.
Systematic characterization of biotin interference across multiple immunoassay platforms demonstrating that supplemental doses as low as 5 mg per day produce clinically significant false results in TSH, free T4, troponin, PTH, and other streptavidin-biotin assays, providing the quantitative basis for the FDA safety advisory and the clinical guidance to stop biotin before laboratory testing.
Study demonstrating that biotin regulates the expression of multiple glucose metabolism genes beyond GCK, including phosphoenolpyruvate carboxykinase (PEPCK) and pyruvate carboxylase itself, establishing that biotin has broad transcriptional regulatory effects on hepatic and beta-cell glucose metabolism at pharmacological concentrations.
Characterization of biotinidase as both a biotin-recycling enzyme and a biotinyl group transferase capable of biotinylating histones, establishing the mechanistic basis for histone biotinylation as an epigenetic modification catalyzed by biotinidase in the nucleus and laying the foundation for understanding biotin-dependent epigenetic regulation.
Review summarizing two decades of research on histone biotinylation by Zempleni's group, detailing H4K12 biotinylation as a chromatin compaction mark, the depletion of this mark in biotin deficiency, its restoration with supplementation, and the functional consequences for gene silencing and genomic stability.
Comprehensive analysis of biotin requirements in humans using factorial modeling, metabolic balance studies, and dose-response experiments, establishing the adequate intake of 30 micrograms per day for adults and quantifying the contribution of intestinal bacterial synthesis to total biotin supply, which is substantial but highly variable between individuals.
Phase III randomized controlled trial of 100 mg per day biotin (MD1003) in progressive MS patients demonstrating confirmed disability improvement in 12.6 percent of the biotin group versus 0 percent in the placebo group after 12 months, establishing the first evidence of disease modification in progressive MS with a simple vitamin intervention and confirming the pharmacological mechanism proposed by the pilot studies.